Second Sight Medical (EYES) Reports In-Line Q4 EPS

Second Sight Medical (NASDAQ: EYES) reported Q4 Adj. EPS ex-items of ($0.17), in-line with the analyst estimate of ($0.17). Revenue for the quarter came in at $715 thousand, versus $2.4 million reported last year.

For earnings history and earnings-related data on Second Sight Medical (EYES) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Cellebrite DI Ltd. (CLBT) Tops Q2 EPS by 4c ; Offers Guidance
• Stratasys (SSYS) Tops Q2 EPS by 2c ;; Offers Guidance